Evidence for an endogenous peptide ligand for the phencyclidine receptor.
R Quirion, D A DiMaggio, E D French, Patricia C. Contreras, J Shiloach, C B Pert, H Everist, A Pert, Thomas L. O'donohue
Peptides 1984 DOI: 10.1016/0196-9781(84)90124-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Basic science or biochemical study Peer reviewed |
|---|---|
| Population | Porcine brain tissue and rat brain membranes |
| Key points | The authors report that a small peptide of approximately 3000 daltons from porcine brain selectively competes with [3H]-PCP for binding to rat brain membranes, does not interact with benzodiazepine, neurotensin, or mu, delta, or kappa opioid receptors, and shows PCP-like activity in two bioassays. They conclude it is likely to be an endogenous ligand for the PCP receptor. |
Abstract
Porcine brain contained an active factor that competed with [3H]-phencyclidine (PCP) for binding to rat brain membranes. On reverse phase high pressure liquid chromatography, the active material eluted between 38-42% acetonitrile. Gel filtration chromatography of the factor predicted a molecular weight of approximately 3000 daltons. The endogenous substance appeared to be selective for PCP receptors as it did not interact with either benzodiazepine, neurotensin, nor with mu, delta, or kappa opioid receptors. The active material showed a heterogenous distribution in brain, with highest concentrations found in hippocampus and cortex. It is likely to be a small peptide since various proteases eliminated or markedly reduced the potency of the compound in a [3H]-PCP binding assay. The material also possessed PCP-like activity in two bioassays. Like PCP, it induced contralateral rotational behavior after unilateral intranigral injection and depressed spontaneous cell activity after iontophoretic micropressure application in hippocampus and cerebral cortex. Thus, this small peptide is likely to be an endogenous ligand for the PCP receptor.
Citations in the library
Cited by 6
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Neuroscience and the Near-Death Experience: Roles for the NMSA-PCP receptor, the sigma receptor and the endopsychosins Medical Hypotheses 1990
- The Ketamine Model of the Near-Death Experience: A Central Role for the N-Methyl-D-Aspartate Receptor Journal of Near-Death Studies March 1, 1997
- A Review of NMDA Receptors and the Phencyclidine Model of Schizophrenia Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy January 2, 1996
- Gestational exposure to phencyclidine (PCP) in rats decreases PCP binding sites in term fetal brain International Journal of Developmental Neuroscience 1988
and 1 more in the library
Cites 4
- The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate British Journal of Pharmacology June 1, 1983
- Specific binding of [3H]phencyclidine in rat central nervous tissue: further characterization and technical considerations. Brain Research January 10, 1983
- Stereospecific binding of 3H-phencyclidine in brain membranes. Life Sciences June 21, 1982
- Phencyclidine-like discriminative effects of opioids in the rat. Journal of Pharmacology and Experimental Therapeutics September 1, 1980